Morning Star | Over 20 Qiming Venture Partners Portfolio Companies Win 30 Awards in Zero2IPO's 2025 VENTURE50
The VENTURE50 rankings are China's bellwether for high-growth enterprise investment.
Recently, the 2025 VENTURE50 results were officially announced, organized by Zero2IPO and PEDaily. This year's awards continued the Fengyun 50 and Xinya 50 categories, alongside three industry tracks: Artificial Intelligence, Hard Tech, and Life Sciences. The Fengyun 50 recognizes unlisted companies that have raised beyond Series B or were founded before 2022, while the Xinya 50 honors unlisted companies at Series B or earlier stages founded after 2022. The AI 50, Hard Tech 50, and Life Sciences 50 highlight high-growth enterprises with standout performance in their respective sectors during 2025.
Portfolio companies of Qiming Venture Partners — Galaxy Universal, Zhipu AI, Mech-Mind Robotics, Minghui Healthcare, Cornerstone Robotics, Wushuang Medical, Insilico Medicine, Tashi Zhihang, Infinigence AI, Ze'an Biopharmaceutical, Axera, Houmo AI, MiFei Technology, Biren Technology, Zenitar, Tingsheng Technology, Shize Biotech, Wushuang Medical, Tianchen Biotech, Tupu Medical, Xiyuan Anjian, and Yijielike — received a total of 30 awards.
Galaxy Universal, Zhipu AI, Mech-Mind Robotics
Minghui Healthcare, Cornerstone Robotics
Wushuang Medical, Insilico Medicine
Selected for
2025 Venture50 Fengyun List
Tashi Zhihang, Infinigence AI, Ze'an Biopharmaceutical
Selected for
2025 Venture50 Xinya List
Galaxy Universal, Zhipu AI
Mech-Mind Robotics, Tashi Zhihang
Selected for
2025 PEDaily AI Venture50
Axera, Houmo AI, MiFei Technology, Biren Technology
Selected for
2025 PEDaily Hard Tech Venture50
Zenitar, Tingsheng Technology, Minghui Healthcare
Cornerstone Robotics, Ze'an Biopharmaceutical, Shize Biotech
Wushuang Medical, Tianchen Biotech, Tupu Medical
Xiyuan Anjian, Yijielike, Insilico Medicine
Selected for
2025 PEDaily Life Sciences Venture50
The VENTURE50 awards, refined over two decades, have become a leading barometer for high-growth enterprise investment in China. The 2025 selection process combined multiple rounds of online evaluation with offline matchmaking, creating an efficient interactive platform for tech ventures and investment institutions. This actively facilitated industry-capital alignment, discovering and witnessing countless outstanding tech enterprises grow from "sprouts" to "unicorns," driving deep integration of industry and capital to serve the high-quality development of China's tech innovation sector.
Among the 2025 VENTURE50 Fengyun 50 and Xinya 50 honorees, AI companies dominated, accounting for 49% of the total. Embodied AI, generative AI, and "AI + vertical scenarios" became focal points for venture capital, pushing AI from technology proof-of-concept toward commercial deployment. With policy support and market demand forming a triple engine of "technology-capital-scenarios," the AI industry is transitioning from a "model explosion phase" to a "scenario fulfillment phase," injecting strong momentum into high-quality development.
Source | PEDaily
Past Highlights
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare innovation.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative enterprises, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Hepaloc Therapeutics, Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, among others.